ArticleAdvanced healthcare materials2026
Increased Anti-Psoriatic Effect of Anti-Inflammatory Dendrimers Using Fluid Catanionic Vesicle-Based Topical Formulations.
Article in Advanced healthcare materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Psoriasis is a chronic inflammatory skin disease requiring effective anti-inflammatory treatments. The IMD-006 dendrimer exhibits promising immunomodulatory effects, but optimized formulations are needed to improve skin penetration. This study describes fluid vesicle formulations to enhance IMD-006 delivery and evaluates their anti-psoriatic efficacy in a murine model, offering potential for innovative topical therapies. Due to IMD-006's hydrolytic instability at pH 7, more stable analogues, IMD-036 and IMD-046, are designed with phosphoramidate and triazine branching points, improving hydrolytic resistance. Fluorescent derivatives are also synthesized using copper-free click chemistry for biological studies. These dendrimers are actively internalized by monocytes, promoting an anti-inflammatory phenotype. Encapsulation in highly fluid TriCat catanionic vesicles significantly enhances cellular uptake and skin penetration, particularly for IMD-006 and IMD-036, facilitating deeper tissue diffusion without systemic exposure. A xanthan-based hydrogel incorporating TriCat vesicles loaded with these dendrimers is developed for topical application, improving stability, sustained drug release, and skin permeability. In a psoriatic mouse model, TriCat/IMD-006 and TriCat/IMD-036 formulations significantly reduced disease severity ( p < 0.0001 and p < 0.05 respectively), producing clinical and histopathological outcomes equivalent to corticosteroid treatment. These findings highlight the potential of dendrimer-based formulations as effective topical treatments for psoriasis, offering an alternative to conventional corticosteroids.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.